These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 17659208)
21. Clinical impact and relevance of antibiotic resistance. French GL Adv Drug Deliv Rev; 2005 Jul; 57(10):1514-27. PubMed ID: 15978698 [TBL] [Abstract][Full Text] [Related]
22. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E; J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704 [TBL] [Abstract][Full Text] [Related]
23. New antimicrobial agents for the treatment of bacterial infections in cancer patients. Rolston KV Hematol Oncol; 2009 Sep; 27(3):107-14. PubMed ID: 19569253 [TBL] [Abstract][Full Text] [Related]
24. The need for new antibiotics. Livermore DM Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():1-9. PubMed ID: 15522034 [TBL] [Abstract][Full Text] [Related]
25. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Cornaglia G; Rossolini GM Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369 [TBL] [Abstract][Full Text] [Related]
26. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Zhanel GG; DeCorby M; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; Mulvey MR; Hoban DJ; Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913 [TBL] [Abstract][Full Text] [Related]
27. What's new on the antimicrobial horizon? Song JH Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S207-13. PubMed ID: 19134521 [TBL] [Abstract][Full Text] [Related]
28. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina. Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C; Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645 [TBL] [Abstract][Full Text] [Related]
29. Bacterial resistance to antibiotics: modified target sites. Lambert PA Adv Drug Deliv Rev; 2005 Jul; 57(10):1471-85. PubMed ID: 15964098 [TBL] [Abstract][Full Text] [Related]
31. The challenge of antibiotic resistant bacterial pathogens: the medical need, the market and prospects for new antimicrobial agents. Payne D; Tomasz A Curr Opin Microbiol; 2004 Oct; 7(5):435-8. PubMed ID: 15451496 [No Abstract] [Full Text] [Related]
32. Microbiology of antibiotic resistance in Staphylococcus aureus. Appelbaum PC Clin Infect Dis; 2007 Sep; 45 Suppl 3():S165-70. PubMed ID: 17712742 [TBL] [Abstract][Full Text] [Related]
38. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy. Roveta S; Marchese A; Debbia EA Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470 [TBL] [Abstract][Full Text] [Related]
39. The challenge of multidrug resistance: the treatment of gram-negative rod infections. Levin AS; Oliveira MS Shock; 2008 Oct; 30 Suppl 1():30-3. PubMed ID: 18704012 [TBL] [Abstract][Full Text] [Related]
40. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients. Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]